title: Chemotherapy for metastatic melanoma: time for a change?
abstract: Melanoma is a neoplasm with a rising incidence. Early-stage melanoma is curable, but advanced, metastatic melanoma almost uniformly is fatal, and patients with such advanced disease have a short median survival. Systemic therapy remains unsatisfactory, inducing complete durable responses in a small minority of patients. For the current review, the authors focused on the current role of cytotoxic chemotherapy in the treatment of metastatic melanoma and the future prospects for improvements for multiagent chemotherapy and chemotherapy combined with immunomodulatory and/or molecularly targeted agents. They discuss roles of single-agent chemotherapy, combination chemotherapy, combinations of chemotherapy with immunomodulatory or hormone agents, biochemotherapy, and combination chemotherapy with targeted therapies.
authors.affiliation: First Department of Internal Medicine, University of Athens, Athens, Greece. hgogas@hol.gr
authors.forename: Helen J
authors.initials: HJ
authors.lastname: Gogas
authors.forename: John M
authors.initials: JM
authors.lastname: Kirkwood
authors.forename: Vernon K
authors.initials: VK
authors.lastname: Sondak
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D006801:Humans; D008545:Melanoma / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents